FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2112417555> ?p ?o ?g. }

• W2112417555 endingPage "4161" @default.
• W2112417555 startingPage "4152" @default.
• W2112417555 abstract "Purpose To study the toxicity and pharmacokinetic-pharmacodynamic profile of 17-allylamino, 17- demethoxygeldanamycin (17-AAG) and to recommend a dose for phase II trials. Patients and Methods This was a phase I study examining a once-weekly dosing schedule of 17-AAG. Thirty patients with advanced malignancies were treated. Results The highest dose level reached was 450 mg/m 2 /week. The dose-limiting toxicities (DLTs) encountered were grade 3 diarrhea in three patients (one at 320 mg/m 2 /week and two at 450 mg/m 2 /week) and grade 3 to 4 hepatotoxicity (AST/ALT) in one patient at 450 mg/m 2 /week. Two of nine DLTs were at the highest dose level. Two patients with metastatic melanoma had stable disease and were treated for 15 and 41 months, respectively. The dose versus area under the curve-relationship for 17-AAG was linear (r 2 = .71) over the dose range 10 to 450 mg/m 2 /week, with peak plasma concentrations of 8,998 μg/L (standard deviation, 2,881) at the highest dose level. After the demonstration of pharmacodynamic changes in peripheral blood leukocytes, pre- and 24 hours post-treatment, tumor biopsies were performed and demonstrated target inhibition (c-RAF-1 inhibition in four of six patients, CDK4 depletion in eight of nine patients and HSP70 induction in eight of nine patients) at the dose levels 320 and 450 mg/m 2 /week. It was not possible to reproducibly demonstrate these changes in biopsies taken 5 days after treatment. Conclusion It has been possible to demonstrate that 17-AAG exhibits a tolerable toxicity profile with therapeutic plasma concentrations and target inhibition for 24 hours after treatment and some indications of clinical activity at the dose level 450 mg/m 2 /week. We recommend this dose for phase II clinical trials." @default.
• W2112417555 created "2016-06-24" @default.
• W2112417555 creator A5003965204 @default.
• W2112417555 creator A5013143263 @default.
• W2112417555 creator A5018384442 @default.
• W2112417555 creator A5032401979 @default.
• W2112417555 creator A5035792728 @default.
• W2112417555 creator A5041415652 @default.
• W2112417555 creator A5053304892 @default.
• W2112417555 creator A5057877920 @default.
• W2112417555 creator A5058014829 @default.
• W2112417555 creator A5062762491 @default.
• W2112417555 creator A5067780498 @default.
• W2112417555 creator A5072568726 @default.
• W2112417555 creator A5075685380 @default.
• W2112417555 creator A5091648628 @default.
• W2112417555 creator A5084138903 @default.
• W2112417555 date "2005-06-20" @default.
• W2112417555 modified "2023-10-04" @default.
• W2112417555 title "Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies" @default.
• W2112417555 cites W1515542254 @default.
• W2112417555 cites W1583373908 @default.
• W2112417555 cites W1892438397 @default.
• W2112417555 cites W1964826325 @default.
• W2112417555 cites W1970392870 @default.
• W2112417555 cites W1999307044 @default.
• W2112417555 cites W2014514145 @default.
• W2112417555 cites W2014790326 @default.
• W2112417555 cites W2046044279 @default.
• W2112417555 cites W2047782251 @default.
• W2112417555 cites W2049546697 @default.
• W2112417555 cites W2062782211 @default.
• W2112417555 cites W2074579328 @default.
• W2112417555 cites W2084582184 @default.
• W2112417555 cites W2088938008 @default.
• W2112417555 cites W2099302625 @default.
• W2112417555 cites W2111187586 @default.
• W2112417555 cites W2123056940 @default.
• W2112417555 cites W2145037225 @default.
• W2112417555 cites W2162107265 @default.
• W2112417555 cites W2168700356 @default.
• W2112417555 cites W2173081403 @default.
• W2112417555 doi "https://doi.org/10.1200/jco.2005.00.612" @default.
• W2112417555 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15961763" @default.
• W2112417555 hasPublicationYear "2005" @default.
• W2112417555 type Work @default.
• W2112417555 sameAs 2112417555 @default.
• W2112417555 citedByCount "460" @default.
• W2112417555 countsByYear W21124175552012 @default.
• W2112417555 countsByYear W21124175552013 @default.
• W2112417555 countsByYear W21124175552014 @default.
• W2112417555 countsByYear W21124175552015 @default.
• W2112417555 countsByYear W21124175552016 @default.
• W2112417555 countsByYear W21124175552017 @default.
• W2112417555 countsByYear W21124175552018 @default.
• W2112417555 countsByYear W21124175552019 @default.
• W2112417555 countsByYear W21124175552020 @default.
• W2112417555 countsByYear W21124175552021 @default.
• W2112417555 countsByYear W21124175552022 @default.
• W2112417555 countsByYear W21124175552023 @default.
• W2112417555 crossrefType "journal-article" @default.
• W2112417555 hasAuthorship W2112417555A5003965204 @default.
• W2112417555 hasAuthorship W2112417555A5013143263 @default.
• W2112417555 hasAuthorship W2112417555A5018384442 @default.
• W2112417555 hasAuthorship W2112417555A5032401979 @default.
• W2112417555 hasAuthorship W2112417555A5035792728 @default.
• W2112417555 hasAuthorship W2112417555A5041415652 @default.
• W2112417555 hasAuthorship W2112417555A5053304892 @default.
• W2112417555 hasAuthorship W2112417555A5057877920 @default.
• W2112417555 hasAuthorship W2112417555A5058014829 @default.
• W2112417555 hasAuthorship W2112417555A5062762491 @default.
• W2112417555 hasAuthorship W2112417555A5067780498 @default.
• W2112417555 hasAuthorship W2112417555A5072568726 @default.
• W2112417555 hasAuthorship W2112417555A5075685380 @default.
• W2112417555 hasAuthorship W2112417555A5084138903 @default.
• W2112417555 hasAuthorship W2112417555A5091648628 @default.
• W2112417555 hasBestOaLocation W21124175551 @default.
• W2112417555 hasConcept C111113717 @default.
• W2112417555 hasConcept C112705442 @default.
• W2112417555 hasConcept C126322002 @default.
• W2112417555 hasConcept C2777288759 @default.
• W2112417555 hasConcept C29730261 @default.
• W2112417555 hasConcept C71924100 @default.
• W2112417555 hasConcept C76318530 @default.
• W2112417555 hasConcept C90924648 @default.
• W2112417555 hasConcept C98274493 @default.
• W2112417555 hasConceptScore W2112417555C111113717 @default.
• W2112417555 hasConceptScore W2112417555C112705442 @default.
• W2112417555 hasConceptScore W2112417555C126322002 @default.
• W2112417555 hasConceptScore W2112417555C2777288759 @default.
• W2112417555 hasConceptScore W2112417555C29730261 @default.
• W2112417555 hasConceptScore W2112417555C71924100 @default.
• W2112417555 hasConceptScore W2112417555C76318530 @default.
• W2112417555 hasConceptScore W2112417555C90924648 @default.
• W2112417555 hasConceptScore W2112417555C98274493 @default.
• W2112417555 hasIssue "18" @default.
• W2112417555 hasLocation W21124175551 @default.
• W2112417555 hasLocation W21124175552 @default.

• next